Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | HTR2C | P28335 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.74 |
| ▸ | HTR5A | P47898 | 1/20 | 0.74 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.74 |
| ▸ | PARP1 | P09874 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466239 | 1.00 | TAAR1 (0.96) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Hydrochloric Acid SCHEMBL30741597 | 0.98 | TAAR1 (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Hydrochloric Acid SCHEMBL2243782 | 0.98 | TAAR1 (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL620253 | 0.89 | TAAR1 (0.78) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL3045846 | 0.87 | HTR2A (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL29736160 | 0.87 | HTR2A (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL2979137 | 0.86 | TAAR1 (0.73) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Tryptoline SCHEMBL12190178 | 0.85 | NISCH (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Tryptoline SCHEMBL171755 | 0.85 | NISCH (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Tryptoline SCHEMBL29350043 | 0.85 | NISCH (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235434-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2025-07-24 | — | — | US | claimed |
| EP-4508053-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2025-02-19 | — | — | EP | claimed |
| WO-2023198597-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-10-19 | — | — | WO | claimed |
| EP-2145887-B1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM LLC (US) | 2016-04-27 | — | — | EP | claimed |
| WO-2011139242-A2 | PROCESS FOR THE PREPARATION OF 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE DERIVATIVES | USTAV EXPIREMENTÁLNEJ FARMAKOLÓGIE A TOXIKOLÓGIE SAV (SK) | 2011-11-10 | — | — | WO | claimed |
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | claimed |
| EP-2236511-A2 | LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | Alla Chem, LLC. (US) | 2010-10-06 | — | — | EP | claimed |
| EP-2145887-A2 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1910361-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1863810-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | claimed |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007016353-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-08 | — | — | WO | claimed |
| WO-2006101434-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | claimed |
| EP-1015451-B1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA NV (BE) | 2003-06-18 | — | — | EP | claimed |
| US-20020103209-A1 | Tetrahydro gamma-carbolines | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2002-08-01 | — | — | US | claimed |
| US-6303614-B1 | FOR THERAPY PSYCHOTIC DISORDER SELECTED FROM DEPRESSION, ANXIETY OR PSYCHOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-16 | — | — | US | claimed |
| EP-1015451-A1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-05 | — | — | EP | claimed |
| EP-0905136-A1 | Tetrahydro gamma-carbolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-31 | — | — | EP | claimed |
| WO-1999012926-A1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-18 | — | — | WO | claimed |
| US-4174453-A | HYDROGENATION, ACIDFICATION | ENDO LABORATORIES, INC. (US) | 1979-11-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235434-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | RIF1, FNTB, Q6ZSR9 | TAAR1 4264/4885HTR2A 4372/4885HTR2C 4784/4885 |
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ADRB3, ADRA2C, ADRB2 | TAAR1 83/4885HTR2A 51/4885HTR2C 10/4885 |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | TAAR1 2883/4885HTR2A 80/4885HTR2C 82/4885 |
| US-20020103209-A1 | Tetrahydro gamma-carbolines | OPRD1, CYP1B1, CBR1 | TAAR1 943/4885HTR2A 444/4885HTR2C 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.